|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, et al: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hemminki K and Li X: Familial risks in
nervous system tumors. Cancer Epidemiol Biomarkers Prev.
12:1137–1142. 2003.PubMed/NCBI
|
|
4
|
Scheurer ME, Etzel CJ, Liu M, El-Zein R,
Airewele GE, Malmer B, Aldape KD, Weinberg JS, Yung WK and Bondy
Ml: Aggregation of cancer in first-degree relatives of patients
with glioma. Cancer Epidemiol Biomarkers Prev. 16:2491–2495. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, et al: An integrated genomic analysis of human
glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greenman C, Stephens P, Smith R, Dalgliesh
GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C,
et al: Patterns of somatic mutation in human cancer genomes.
Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sjöblom T, Jones S, Wood LD, Parsons DW,
Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al:
The consensus coding sequences of human breast and colorectal
cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lichtenstein P, Holm NV, Verkasalo PK,
Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki
K: Environmental and heritable factors in the causation of
cancer-analyses of cohorts of twins from Sweden, Denmark and
Finland. N Engl J Med. 343:78–85. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bentivegna S, Zheng J, Namsaraev E,
Carlton VE, Pavlicek A, Moorhead M, Siddiqui F, Wang Z, Lee L,
Ireland JS, et al: Rapid identification of somatic mutations in
colorectal and breast cancer tissues using mismatch repair
detection (MRD). Hum Mutat. 29:441–450. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Lonardo A, Nasi S and Pulciani S:
Cancer: we should not forget the past. J Cancer. 6:29–39. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Erstad DJ and Jr JC: Mutational analysis
of merkel cell carcinoma. Cancers (Basel). 6:2116–2136. 2014.
View Article : Google Scholar
|
|
16
|
Schubert KM and Duronio V: Distinct roles
for extracellular-signal-regulated protein kinase (ERK)
mitogen-activated protein kinases and phosphatidylinositol 3-kinase
in the regulation of Mcl-1 synthesis. Biochem J. 356:473–480. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chao JR, Wang JM, Lee SF, Peng HW, Lin YH,
Chou CH, et al: Mcl-1 is an immediate-early gene activated by the
granulocyte-macrophage colony-stimulating factor (GMCSF) signaling
pathway and is one component of the GM-CSF viability response. Mol
Cell Biol. 18:4883–4898. 1998.PubMed/NCBI
|
|
18
|
Nijhawan D, Fang M, Traer E, Zhong Q, Gao
W, Du F and Wang X: Elimination of Mcl-1 is required for the
initiation of apoptosis following ultraviolet irradiation. Genes
Dev. 17:1475–1486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varela I, Tarpey P, Raine K, Huang D, Ong
CK, et al: Exome sequencing identifies frequent mutation of the
SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469:539–542.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones S, Wang TL, Shih IM, Mao TL,
Nakayama K, et al: Frequent mutations of chromatin remodeling gene
ARID1A in ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wen PY and Kesari S: Malignant Gliomas in
Adults. N Engl J Medicine. 359:492–507. 2008. View Article : Google Scholar
|
|
22
|
Kozopas KM, Yang T, Buchan HL, Zhou P and
Craig RW: MCL1, a gene expressed in programmed myeloid cell
differentiation, has sequence similarity to Bcl-2. Proc Natl Acad
Sci USA. 90:3516–3520. 1993. View Article : Google Scholar
|
|
23
|
Day CL, Chen L, Richardson SJ, Harrison
PJ, Huang DCS and Hinds MG: Solution structure of prosurvival Mcl-1
and characterization of its binding by proapoptotic BH3-only
ligands. J Biol Chem. 280:4738–4744. 2005. View Article : Google Scholar
|
|
24
|
Clohessy JG, Zhuang J and Brady HJM:
Characterisation of Mcl-1 cleavage during apoptosis of
haematopoietic cells. Br J Haemato. 125:655–665. 2004. View Article : Google Scholar
|
|
25
|
Domina AM, Smith JH and Craig RW: Myeloid
cell leukemia 1 is phosphorylated through two distinct pathways,
one associated with extracellular signal regulated kinase
activation and the other with G2/M accumulation or protein
phosphatase 1/2A inhibition. J Biol Chem. 275:21688–21694. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Domina AM, Vrana JA, Gregory MA, Hann SR
and Craig RW: MCL1 is phosphorylated in the PEST region and
stabilized upon ERK activation in viable cells and at additional
sites with cytotoxic okadaic acid or taxol. Oncogene. 23:5301–5315.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong Q, Gao W, Du F and Wang X:
Mule/ARFBP1, a BH3-only E3 ubiquitin ligase, catalyzes the
polyubiquitination of Mcl-1 and regulates apoptosis. Cell.
121:1085–1095. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao
Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJR, Hsu JM, Kuo
HP, Lin CY, Tsai FJ, Li LY, Tsai CH and Hung MC: Down-regulation of
myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by
sorafenib facilitates chemosensitization in breast cancer. Cancer
Res. 68:6109–6117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Inoshita S, Takeda K, Hatai T, Terada Y,
Sano M, Hata J, Umezawa A and Ichijo H: Phosphorylation and
inactivation of myeloid cell leukemia 1 by JNK in response to
oxidative stress. J Biol Chem. 277:43730–43734. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morel C, Carlson SM, White FM and Davis
RJ: Mcl-1 integrates the opposing actions of signaling pathways
that mediate survival and apoptosis. Mol Cell Biol. 29:3845–3852.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maurer U, Charvet C, Wagman AS, Dejardin E
and Green DR: Glycogen synthase kinase-3 regulates mitochondrial
outer membrane permeabilization and apoptosis by destabilization of
Mcl-1. Mol Cell. 21:749–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Michels J, Johnson PW and Packham G:
Mcl-1. Int J Biochem Cell Biol. 37:267–71. 2005. View Article : Google Scholar
|
|
33
|
Craig RW: Mcl-1 provides a window on the
role of the Bcl-2 family in cell proliferation, differentiation and
tumorigenesis. Leukemia. 16:444–454. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rinkenberger JL, Horning S, Klocke B, Roth
K and Korsmeyer SJ: Mcl-1 deficiency results in periimplantation
embryonic lethality. Genes Dev. 14:23–27. 2000.PubMed/NCBI
|
|
35
|
Opferman JT, Letai A, Beard C, Sorcinelli
MD, Ong CC and Korsmeyer SJ: Development and maintenance of B and T
lymphocytes requires antiapoptotic Mcl-1. Nature. 426:671–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Willis SN, Chen L, Dewson G, Wei A, Naik
E, Fletcher JI, et al: Proapoptotic Bak is sequestered by Mcl-1 and
Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes
Dev. 19:1294–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McDonnell TJ and Korsmeyer SJ: Progression
from lymphoid hyperplasia to high-grade malignant lymphoma in mice
transgenic for the t(14; 18). Nature. 349:254–256. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou P, Levy NB, Xie H, et al: Mcl-1
transgenic mice exhibit a high incidence of B-cell lymphoma
manifested as a spectrum of histologic subtypes. Blood.
97:3902–3909. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Townsend KJ, Zhou P, Qian L, et al:
Regulation of Mcl-1 through a serum response factor/Elk-1-mediated
mechanism links expression of a viability-promoting member of the
Bcl-2 family to the induction of hematopoietic cell
differentiation. J Biol Chem. 274:1801–1813. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thallinger C, Wolschek MF, Maierhofer H,
et al: Mcl-1 is a novel therapeutic target for human sarcoma:
synergistic inhibition of human sarcoma xenotransplants by a
combination of mcl-1 antisense oligonucleotides with low-dose
cyclophosphamide. Clin Cancer Res. 10:4185–4191. 2004. View Article : Google Scholar : PubMed/NCBI
|
